Antibody

11개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved11 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyCurated CoreFDAstaleAstraZenecaApproved

durvalumab (Imfinzi, MEDI4736)

NSCLC (Stage III consolidation), SCLC, biliary tract, HCC · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 750Status Approved
AntibodyCurated CoreFDAstaleJazz PharmaceuticalsApproved

zanidatamab (Ziihera, ZW25, zanidatamab-hrii)

First-line HER2-positive gastric, GEJ, or esophageal adenocarcinoma; previously treated HER2-positive biliary tract can… · HER2 (biparatopic)

#HER2biparatopic#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 35Status Approved
AntibodyLimited DatastaleHuiKai LiPhase 2

Pucotenlimab (Pucotenlimab)

Biliary Tract Cancer (BTC); EGFR-positive Advanced Biliary Tract Carcinoma · Nasopharyngeal Cancinoma (NPC)

#NasopharyngealCancinomaNPC#Antibody#Phase2#monoclonal-antibody#BiliaryTractCancerBTC+2
Trials 42Status Recruiting
AntibodyLimited DatastaleXencor, Inc.Phase 2

XmAb20717 (XmAb20717)

Biliary Tract Cancer · Melanoma

#Melanoma#Antibody#Phase2#monoclonal-antibody#BiliaryTractCancer+1
Trials 9Status Recruiting
AntibodyLimited DatastaleCentre Hospitalier Universitair…Phase 2

durvalumab (Imfinzi, MP0317 + Gemcitabine + Cisplatine + Durvalumab)

Advanced Biliary Tract Carcinoma · Advanced Biliary Tract Carcinoma

#AdvancedBiliaryTractCarcinoma#Antibody#Phase2#monoclonal-antibody#Centre
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 2

durvalumab (Imfinzi, Pemigatinib and Durvalumab)

Biliary Tract Carcinoma; Cholangiocarcinoma · Biliary Tract Carcinoma

#BiliaryTractCarcinoma#Antibody#Phase2#monoclonal-antibody#Cholangiocarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

sequential group (Sequential treatment of bevacizumab combined with atezolizumab, Sequential treatment of bevacizumab combined with atezolizumab (sequential group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleEastern Hepatobiliary Surgery H…Phase 3

same period group (Simultaneous treatment of bevacizumab combined with atezolizumab, Simultaneous treatment of bevacizumab combined with atezolizumab (same period group))

HCC - Hepatocellular Carcinoma · HCC - Hepatocellular Carcinoma

#HCC-HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#Eastern
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

JS001 (TORIPALIMAB INJECTION, TORIPALIMAB INJECTION(JS001 ))

Biliary Tract Cancer (BTC) · Biliary Tract Cancer (BTC)

#BiliaryTractCancerBTC#Antibody#Phase2#monoclonal-antibody#Junshi
Trials 1Status Recruiting
AntibodyLimited DatastaleWest China HospitalPhase 2

Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors (Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors)

Cancer of Biliary Duct · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#CancerofBiliaryDuct+1
Trials 1Status Recruiting
AntibodyLimited DatastaleShanghai Zhongshan HospitalPhase 2

cardonilizumab (cardonilizumab)

Biliary Tract Cancer; Candonilimab · Biliary Tract Cancer

#BiliaryTractCancer#Antibody#Phase2#monoclonal-antibody#Candonilimab+1
Trials 1Status Recruiting